Arbutus Biopharma (ABUS) announced that the FDA has granted Fast Track designation for imdusiran for the treatment of chronic hepatitis B.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABUS:
- Roivant Sciences price target raised to $34 from $30 at Jefferies
- Arbutus Biopharma price target lowered to $5.50 from $7 at Jefferies
- Arbutus Boosted by $2.25 Billion LNP Settlement and Hepatitis B Trial Progress
- Midday Fly By: Stocks climb as oil prices pull back
- Why Is Moderna (MRNA) Stock Surging Today, 3/4/26?